Combined histamine H1/H2 receptor antagonists: Part I. Pharmacological hybrids with pheniramine- and roxatidine-like substructures

European Journal of Pharmaceutical Sciences

Volumn 6, Issue 3, 1998, Pages 177-186

  Schulze, Frank R ^a   Buschauer, Armin ^b   Schunack, Walter ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Histamine; Histamine H1 receptor antagonists; Histamine H2 receptor antagonists; Pheniramine; Roxatidine

Indexed keywords

CHLORPHENIRAMINE; CIMETIDINE; HISTAMINE H1 RECEPTOR; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR; HISTAMINE H2 RECEPTOR ANTAGONIST; RANITIDINE; PHENIRAMINE; PIPERIDINE DERIVATIVE; ROXATIDINE ACETATE;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; GUINEA PIG; HEART RIGHT ATRIUM; ILEUM; IN VITRO STUDY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; ANIMAL; DOSE RESPONSE; DRUG EFFECT; HEART ATRIUM; MALE; PHYSIOLOGY; SYNTHESIS;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; GUINEA PIGS; HEART ATRIA; HISTAMINE H1 ANTAGONISTS; HISTAMINE H2 ANTAGONISTS; ILEUM; MALE; PHENIRAMINE; PIPERIDINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0031593476     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-0987(97)10018-5     Document Type: Article

References (22)

1. Arunlakshana, O., Schild, H.O., 1959. Some quantitative uses of drug antagonists. Br. J. Pharmacol. 14, 48-58.
2. 2-Rezeptor-Antagonisten. Klin. Wochenschr. 67, 743-755.
3. 2-receptors. Nature (London) 236, 385-390.
4. 2-receptors. Br. J. Pharmacol. 80, p. 437.
5. 2-Antagonisten. Arzneim.-Forsch. 35, 1025-1029.
6. Buschauer, A., 1989a. Zur Synthese primärer ω-Phenyl-ω-pyridylalkylamine. Arch. Pharm. (Weinheim) 322, 165-171.
7. Buschauer, A., 1989b. Synthesis and in vitro pharmacology of arpromidine and related phenyl(pyridylalkyl)guanidines, a potential new class of positive inotropic drugs. J. Med. Chem. 32, 1963-1970.
8. 2-Prophylaxe im perioperativen Zeitraum. Inn. Med. 17, 129-135.
9. 2-receptors. N. Engl. Reg. Allergy Proc. 7, 126-133.
10. 2 receptor. J. Med. Chem. 35, 2231-2238.
11. Horner, J.K., Skinner, W.A., 1966. A general method for selective N-methylation of substituted tryptamines. Can. J. Chem. 44, 315-319.
12. Kenakin, T.P., 1982. The Schild regression in the process of receptor classification. Can. J. Physiol. Pharmacol. 60, 249-265.
13. Kenakin, T.P., 1993. Competitive antagonism. In: Kenakin, T.P. (Ed.), Pharmacologic Analysis of Drug-receptor Interaction. Raven Press, New York, pp. 278-322.
14. Larsen, R., 1990. Narkosezwischenfälle und Narkosekomplikationen. In: Larsen, R. (Ed.), Anaesthesie, 3rd. ed. Urban and Schwarzenberg, München, pp. 743-754.
15. Lieberman, P., 1990. The use of antihistamines in the prevention and treatment of anaphylaxis and anaphylactoid reactions. J. Allergy Clin. Immunol. 86, 684-686.
16. 2 blockade: a prophylactic principle in anesthesia and surgery against histamine-release responses of any degree of severity. N. Engl. Reg. Allergy Proc. 6, 37-57 and 174-194.
17. 2A receptor specificity, stereoselectivity and modulation of ritanserin-induced depression of 5-HT contractions in rat tail artery. J. Pharm. Pharmacol. 47, 310-316.
18. 2-antagonistische Aktivität von Mepyramin-, Pheniramin- und Cyclizin-Derivaten mit Cyanoguanidin-, Harnstoff- und Nitroethendiamin-Partialstrukturen. Arch. Pharm. (Weinheim) 327, 455-462.
19. Shanklin, J.R., Johnson, C.P., 1985. Method of treating cardiac disorders with N-(aryloxyalkyl)-N′-(aminoalkyl)ureas. US Patent 4500529 (19. Feb. 1985), cf. Chem. Abs. 103, P22300v.
20. Van Rossum, J.M., 1963. Cumulative dose-response curves. II. Technique for the making of dose-response curves in isolated organs and the evaluation of drug parameters. Arch. Int. Pharmacodyn. Ther. 143, 299-329.
21. 2-receptor antagonists containing diphenhydramine and cyproheptadine derivatives. Arch. Pharm. Pharm. Med. Chem. 329, 87-94.
22. Wolff, A.A., Levi, R., 1986. Histamine and cardiac arrhythmias. Circ. Res. 58, 1-16.